Form 4: Catalyst Pharma CFO Kalb Boosts Equity Holdings

Catalyst Pharmaceuticals' Executive Vice President and CFO, Michael Wayne Kalb, reported significant changes in his beneficial ownership of company stock, including new option and RSU grants and the vesting of existing units.

Summary

• Michael Wayne Kalb, Executive Vice President & CFO of Catalyst Pharmaceuticals, Inc. (CPRX), reported changes in his beneficial ownership of company securities.
• On November 21, 2025, Kalb acquired 6,894 shares of common stock, par value $0.001 per share, through the vesting of restricted stock units.
• Concurrently, 2,485 shares of common stock were disposed of on November 21, 2025, to satisfy applicable tax withholding obligations upon the vesting of restricted common stock.
• Following these transactions, Kalb directly beneficially owns 8,606 shares of common stock.
• On November 20, 2025, Kalb was granted 131,536 options to purchase common stock at an exercise price of $22.77, which will vest in three equal tranches on November 20, 2026, November 20, 2027, and November 20, 2028, and expire on November 20, 2032.
• Also on November 20, 2025, Kalb received a grant of 39,701 Restricted Stock Units (RSUs), which will vest in three equal tranches on November 20, 2026, November 20, 2027, and November 20, 2028.
• Kalb's total beneficial ownership of derivative securities now includes 607,235 options and 640,042 Restricted Stock Units.

Sentiment

Score: 7

Explanation: The filing details routine executive compensation events, including new equity grants and vesting of existing awards. This is generally positive as it aligns management's interests with shareholders, though the tax-related disposition is a standard, neutral event.

Positives

• Executive Vice President & CFO Michael Wayne Kalb received a grant of 131,536 options to purchase common stock, aligning his long-term interests with shareholder value.
• Kalb also received a grant of 39,701 Restricted Stock Units (RSUs), further increasing his equity stake in the company.
• The vesting of 6,894 restricted stock units resulted in an increase in direct common stock ownership for the executive.

Negatives

• 2,485 shares of common stock were withheld by the company to cover applicable tax obligations upon the vesting of restricted common stock, representing a disposition of shares.

Future Outlook

The filing indicates future vesting events for options and restricted stock units on various dates through November 2028, suggesting continued long-term incentive alignment for the executive.

Industry Context

This filing represents a routine insider transaction related to executive compensation, common across publicly traded companies in the pharmaceutical industry and beyond, aimed at aligning executive incentives with long-term shareholder value.

Stakeholder Impact

• Shareholders: The grant of new equity awards could lead to minor dilution but also serves to align the Executive Vice President & CFO's long-term interests with shareholder value creation.
• Employees: The compensation structure for a key executive may reflect broader company compensation policies, potentially influencing employee morale and retention.

Next Steps

• Future vesting of 131,536 options in three equal tranches on November 20, 2026, 2027, and 2028.
• Future vesting of 39,701 Restricted Stock Units in three equal tranches on November 20, 2026, 2027, and 2028.
• Future vesting of remaining Restricted Stock Units in tranches on November 21, 2026, and 2027.

Key Dates

Keywords

Catalyst Pharmaceuticals, CPRX, Michael Wayne Kalb, Executive Vice President, CFO, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Compensation, Beneficial Ownership, Stock Grant, Vesting, Tax Withholding